![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Nyxoah’s Obstructive Sleep Apnea Device Earns European Approval
Nyxoah’s Obstructive Sleep Apnea Device Earns European Approval
![](https://www.fdanews.com/ext/resources/test/Device_Images6/Nyxoah_Logo.gif?t=1553035916&width=430)
Nyxoah received the CE Mark for its Genio system, a disruptive neurostimulator intended to treat obstructive sleep apnea (OSA).
The device offers an alternative method of therapy for OSA, which is estimated to affect nearly a billion people and is the most common sleep disordered breathing condition.
The battery-free, minimally invasive device delivers nerve stimulation for moderate to severe OSA patients who have not had success with positive airway pressure therapy.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct